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Abstract
Background: Febrile neutropenia is a frequently occurring and occasionally life-threatening complication of
treatment for childhood cancer. Many biomarkers have been proposed as predictors of adverse events. We aimed
to undertake a systematic review and meta-analysis to summarize evidence on the discriminatory ability of initial
serum biomarkers of febrile neutropenic episodes in children and young people.
Methods: This review was conducted in accordance with the Center for Reviews and Dissemination Methods,
using three random effects models to undertake meta-analysis. It was registered with the HTA Registry of
systematic reviews, CRD32009100485.
Results: We found that 25 studies exploring 14 different biomarkers were assessed in 3,585 episodes of febrile
neutropenia. C-reactive protein (CRP), pro-calcitonin (PCT), and interleukin-6 (IL6) were subject to quantitative meta-
analysis, and revealed huge inconsistencies and heterogeneity in the studies included in this review. Only CRP has
been evaluated in assessing its value over the predictive value of simple clinical decision rules.
Conclusions: The limited data available describing the predictive value of biomarkers in the setting of pediatric
febrile neutropenia mean firm conclusions cannot yet be reached, although the use of IL6, IL8 and procalcitonin
warrant further study.
Background
With multi-modality therapies, children with malignancy
have an excellent chance of survival, with overall rates
approaching 75% [1]. Deaths are largely due to their dis-
ease, but around 16% of deaths are from complications
of therapy [2,3]. This proportion depends on the under-
lying malignancy, and the risk of death from infection
remains high in some groups, for example, acute mye-
loid leukemia [4]. Robust risk stratification, which reli-
ably predicted those children at high risk of
complications, could target more aggressive manage-
ment, where children at very low risk of having a signifi-
cant infection could be treated with reduced intensity
and/or duration of hospitalized antibiotic therapy [5].
There are a wide range of differing approaches to this
risk stratification, largely built on simple clinical data
[6-8], demonstrating only moderate discriminatory
ability.
The ability of specific serum biomarkers to predict
adverse consequences in patients with febrile neutrope-
nia has been explored, for example, C-reactive protein
(CRP), pro-calcitonin (PCT), interleukin-6 (IL6) or inter-
leukin-8 (IL8) [9-12]. These studies have been small in
the numbers of patients and episodes and the research-
ers could not reach definitive conclusions. Drawing
these reports together and synthesizing their results
should improve our understanding of their clinical
usefulness.
Although systematic reviews have been conducted
previously in adults [13] and non- immunocompromised
children [14,15], their results are difficult to compare.
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tropenic fever vary in the nature of the infections which
afflict them [16], implying any review needs to take into
account the specific population under study.
This review aimed to identify, critically appraise and
synthesize information on the use of biomarkers at
initial evaluation for the prediction of the outcome of
febrile neutropenic episodes in children/young adults
and to highlight important problems in the current
methods used in such analyses.
Methods
The review was conducted in accordance with “Systema-
tic reviews: CRD’s guidance for undertaking reviews in
health care” [17] and registered on the HTA Registry of
Systematic Reviews: CRD32009100485. It sought studies
which evaluated the diagnostic ability of serum biomar-
kers of inflammation/infection in children or young peo-
ple aged 0 to 18 years of age, taken at the onset (within
12 hours) of an episode of febrile neutropenia. Both pro-
spective and retrospective cohorts were included, but
those using a case-control approach were excluded as
t h e s eh a v eb e e np r e v i o u s l ys h o w nt oe x a g g e r a t ed i a g -
nostic accuracy estimates [18].
Search strategy and selection criteria
An electronic search strategy (See Additional file 1) was
developed to examine a range of databases from incep-
tion to February 2009, including MEDLINE, EMBASE,
CINAHL, Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects, Health
Technology Assessment Database, Cochrane Central
Register of Controlled Trials, Conference Proceedings
Citation Index - Science and LILACS.
Reference lists of relevant systematic reviews and
included articles were reviewed for further relevant arti-
cles. Published and unpublished studies were sought
without language restrictions. Non-English language stu-
dies were translated. Two reviewers independently
screened the titles and abstracts of studies for inclusion,
and then the full text of retrieved articles. Disagree-
ments were resolved by consensus.
The validity of each study was assessed using 11 of the
14 questions from the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) assessment tool for diag-
nostic accuracy studies [19] (see footnote of Additional
file 2). The QUADAS tool was adapted specifically for
the review, as suggested by current guidance [20], omit-
ting questions on “time between index and reference
test”, “intermediate results” and “explanation of withdra-
wals”. The index test (biomarkers) and reference test
were always examined within a single episode of febrile
neutropenia, making this question indiscriminating.
Tests of biomarkers are not reported as ‘positive’ and
‘negative’, and so “intermediate” results are not found in
these types of studies. Rather than addressing “incom-
plete data” a sav a l i d i t yi t e m ,i tw a sa d d r e s s e di nt h e
data analysis.
Data were extracted by one researcher using a standar-
dized data extraction form and accuracy confirmed inde-
pendently by a second; except with foreign language
papers where a translator working with a reviewer under-
took the extraction. Clinical data extracted included par-
ticipant demographics, geographical location, participant
inclusion/exclusion criteria and antibiotics used. Metho-
dological information included methods used to adjust
the predictive estimate, including the variables consid-
ered, and methods of analysis. The reference standard
outcomes considered relevant included survival, need for
intensive/high-dependency care, single organ impair-
ment, invasive bacterial or fungal infection, presence of
documented infection, including radiologically confirmed
pneumonia, and duration of hospitalization. The sensitiv-
ity and specificity of the biomarkers were extracted, pre-
ferentially as 2 × 2 tables comparing dichotomized test
results against the reference standard. Where data were
only presented as mean and standard deviation, conver-
sion was undertaken using the assumption of Normality
and deriving a 2 × 2 table for cut-offs reported by other
studies (Anzures, Cochrane Colloquium Freiburg 2008).
Methods of analysis/synthesis
Quantitative synthesis was undertaken for studies which
tested the same diagnostic test for similar clinical out-
comes and, where appropriate, was investigated for
sources of heterogeneity.
Three approaches were used for meta-analysis. The
first approach (Method 1) pooled data from the most
commonly reported threshold, using a single data point
from each study that provided relevant information, for
example, each study reporting serum CRP > 50 mg/dL.
This was expressed as the average test sensitivity and
specificity, with a 95% confidence interval. This was cal-
culated by fitting the standard bivariate random effects
model using STATA (version 10) [21] with metandi [22]
and midas [23] for analyses of four or more studies; for
those with fewer than four studies a random effects lin-
ear regression was directly fitted using xmelogit. The
bivariate model is the most commonly used technique
in diagnostic meta-analysis, and has benefits of being
easily interpretable, as it provides a point estimate of the
test accuracy in this context for a defined cut-off value,
and is technically straightforward to undertake. Its
weaknesses lie in the partial use of data from all the
included studies, (since accuracy at multiple test cut-offs
was available from many studies), which may lead to
reduced power and consequent imprecision, and
increased risk of bias from a selective use of data.
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data point from each study, but combined information
from multiple thresholds, for example, serum CRP > 40
mg/dL, > 50 mg/dL and > 90 mg/dL, and the output
was expressed as a hierarchical summary receiver opera-
tor curve (HSROC). The HSROC describes the relation-
ship between sensitivity and specificity derived from the
individual receiver operator curves (ROC) of each study.
In this way, it describes the ‘average’ relationship
between a continuous cut-off value and discriminatory
ability in the ‘average’ population. This increases the
information used in the meta-analysis and better repre-
sents the data. The same routines were used in STATA
(version 10) [21] to produce these estimates. This
approach is again technically straightforward to perform,
and the output allows clinicians to estimate how chan-
ging thresholds will alter the diagnostic utility of the
test under study. Its weaknesses relate to the difficulty
in interpreting exactly what performance is associated
with each cut-off level, and its lack of explicit inclusion
of threshold data when producing the curve.
The third analysis (Method 3) allowed multiple data
points from multiple thresholds from each study to be
included, and was undertaken using a multinomial ran-
dom effects method deriving proportions of the popula-
tion with/without the outcome at each cut-off level of
the biomarkers. These were then used to derive likeli-
hood ratios for each level [24]. This provides the richest
model, including all of the available data from the stu-
dies and should produce the clearest possible descrip-
tions of the predictive value of the biomarkers. This was
accomplished using a previously published method [8]
and non-informative priors. Analyses were undertaken
using WinBUGS 1.4.3 [25]. The code is available upon
request. This method is theoretically superior to the
other methods, as it includes all of the available data,
unlike Method 1, explicitly uses the threshold values,
unlike Method 2, and produces threshold-specific esti-
mates of diagnostic test performance, which can be
interpreted directly by clinicians. It is the most techni-
cally challenging of all the methods used, requiring spe-
cific code to be written for each analysis, rather than the
use of easily available software packages.
Heterogeneity between study results was explored
through consideration of study populations, design, pre-
dictor variables and outcomes. Meta-regression was not
undertaken due to the small number of studies. When
quantitative synthesis was not possible, a narrative
approach was used to synthesize the information.
Results
Three hundred, sixty-eight articles were initially
reviewed, and 72 retrieved for more detailed examina-
tion. Twenty-five articles provided quantitative outcome
data in the form required for the review (see Additional
file 3). The included studies included 2,089 patients and
over 3,585 episodes, assessing 14 different markers of
inflammation or infection (see Table 1). The study out-
comes were grouped into: bacteremia, invasive fungal
infection, significant/documented bacterial infection,
sepsis and death. The population in the studies varied,
with most being a mixture of hematological and solid
malignancies, and very little data from stem cell trans-
plant recipients (see Table 2 for further detail). Thirteen
of these contributed to 1 or more meta-analyses while
the remaining 12 studies did not provide data which
could be included in any meta-analysis. (see Figure 1).
Three biomarkers and 2 outcomes could be included in
the meta-analysis: 11 studies provided data on CRP
[9,26-35] and documented infection. Four studies pro-
vided data on PCT [28,29,31,33] and documented infec-
tion. Four provided data on IL6 [31,36-38] and
documented infection or gram negative bacteremia.
Quality assessment
The studies varied in quality; see Additional file 2. The
major deficiencies in most studies were in a failure to
report if the marker test and outcomes were interpreted
blind to each other. One study [26] assessing CRP
demonstrated a potential contamination of the reference
standard with the diagnostic test: the outcome included
CRP > 150 mg/dl. One short report did not detail the
exact outcome used [39]. Twenty different definitions of
‘febrile neutropenia’ were described, including six defini-
tions of neutropenia ranging from < 200 cells/mm
3 to <
1,000 cells/mm
3; four definitions of peak fever, from >
37.5°C to > 39°C; and six of sustained temperature, from
> 38°C to > 38.5°C over varying durations. There were a
total of 14 combinations to define ‘febrile’.
Table 1 Summary of biomarkers reported across all
included studies
Biomarker Total studies
C reactive protein 20
Interleukin 6 10
Interleukin 8 10
Procalcitonin 8
Tumor necrosis factor a 2
Interleukin 10 1
Monocyte chemoattractant protein-1 1
Erythrocyte sedimentation rate 1
Adenosine deaminase 1
Serum Amyloid A Protein 1
Interleukin 1 1
Interleukin 5 1
Interleukin 12 1
Interleukin 2 - receptor 1
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Citation Underlying conditions Underlying
conditions
Markers
studied
Number
of
patients
Number
of
episodes
Endpoints
studied
Comments
on endpoints
Ammann
2003
Pre-B-cell ALL = 94, Other
diagnosis = 191
CRP 111 285 Significant
bacterial infection
Defined as death from bacterial
infection, a positive culture of
normally sterile body fluids,
radiologically proven
pneumonia, clinically
unequivocal diagnosis of a
bacterial infection, or a serum
CRP above 150 mg/L as an
indirect sign suggesting severe
bacterial infection
Barnes 2002 No data given PCT 37 39 Length of stay Stay of < 5d or ≥5d
de Bont 1999 ALL = 8, AML = 20, CML = 2,
Lymphoma = 16, Solid tumor
=7
CRP, IL6,
IL8
19 72 Bacteremia
Diepold 2008 ALL = 21, AML = 1, JMML = 1,
Relapsed AML after SCT = 1,
Solid tumor = 39,
Hematological disorder after
SCT = 4, Hematological
disorder without SCT = 1
CRP, IL6,
IL8
69 123 Bacteremia
Fever lasting ≥5d
but culture -ve
Dylewska
2005 a and b
No data given CRP, PCT 66 108 Bacteremia
Clinically defined
infections (UTI,
neurological, GI
or respiratory)
Microbiologically
defined other
infection
FUO was the default category
El-Maghraby
2007
ALL = 37, AML = 39,
Lymphoma = 39
CRP, IL8,
MCP
76 85 Bacteremia or
clinically
documented
infection
Hatzistilianou
2007
All patients had ALL CRP, PCT 29 94 Microbiological or
clinically
documented
infection
(excludes viral)
Heney 1992 ALL = 17, AML = 10,
Lymphoma = 2, Solid tumor =
18
CRP, IL6 33 47 Bacteremia
Hitoglou-
Hatzi 2005
All patients had ALL CRP, PCT,
tADA
67 Not
stated
Significant
bacterial infection
Hodge 2006 No overall data given IL8, IL5 31 31 Positive blood
culture
Katz 1992 Haematological malignancy =
82, Solid tumor = 40
CRP 74 122 Clinically or
bacteriologically
documented
infection
Septicemia (+ve
blood cultures
and unwell
clinical
appearance)
Kitanovski
2006
Hematological malignancy =
50, Solid tumor = 18
CRP, PCT,
IL6
32 68 Bacteremia and
clinical sepsis
Clinically or
microbiologically
documented local
infection
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Lehrnbecher
1999
ALL = 17, AML = 7, Lymphoma
= 5, Solid tumor = 27
CRP, PCT,
IL6
56 121 Clinically
documented
infection
Fungal infection
Bacteremia (gram-
type)
FUO was the default category
Lehrnbecher
2004
ALL = 48, AML = 15,
Lymphoma = 16, Histiocytosis
= 1, Solid tumor = 66
IL6, IL8 146 311 Significant
bacterial infection
Defined as bacteremia,
localised infection or
pneumonia
Riikonen
1992
No data given IL6, IL1,
TNF, SAA
46 105 Bacteremia
suspected sepsis
Focal infection
“No infection” was the default
category
Riikonen
1993
ALL = 20, AML = 24, Solid
tumor = 47
CRP 46 91 Bacteremia
suspected sepsis
Focal infection
“No infection” was the default
category
Santolaya
1994
Leukemia = 47, Lymphoma =
17, Solid tumor = 11
CRP 75 85 Documented
bacterial infection
Probable bacterial
infection
Viral infection
Documented bacterial infection
defined as bacteremia (two
sets positive for commensals)
or sterile site infection;
Probable bacterial infection
defined as cultures negative
but severe medical course, for
example, purulent
gingivostomatitis, CXR+; FUO
was the default category
Santolaya
2001
ALL = 40%, AML = 8%,
Relapsed leukemia = 14%,
Lymphoma = 6%, Sarcoma =
17%, Other solid tumor = 15%
CRP 257 447 Invasive bacterial
infection
Defined as positive blood
cultures - 2 for CoNS, positive
bacterial culture from usually
sterile site, or sepsis syndrome
and/or focal organ involvement
and haemodynamic instability
and severe malaise
Santolaya
2002
ALL = 92, AML = 14,
Lymphoma = 10, Solid tumor
=5 4
CRP 170 263 Invasive bacterial
infection
Defined as positive blood
cultures - 2 for CoNS, positive
bacterial culture from usually
sterile site, or sepsis syndrome
and/or focal organ involvement
and haemodynamic instability
and severe malaise
Santolaya
2007
No overall data given CRP 219 373 Death
Santolaya
2008
No overall data given on
diagnoses.
CRP, PCT,
IL8
278 566 Severe sepsis Defined as sepsis + respiratory
or cardiac compromise, or + 2
other-organ compromise) not
apparent during the first 24 h
of admission
Secmeer
2007
ALL and AML = 9, Lymphoma
= 14, Sarcoma = 7,
Histiocytosis = 1, Other solid
tumor = 18
CRP, PCR,
ESR
49 60 Bacteremia
Documented
bacterial infection
(microbiologically
or clinically)
Duration of fever
Soker 2001 ALL = 17, AML = 4, Lymphoma
=2
IL6, IL8,
IL2R, IL1,
TNF-
alpha
23 48 Bacteremia
Spasova 2005 ALL = 23, AML = 1, Lymphoma
= 6, Solid tumor = 11
CRP, IL6,
IL8, IL10
24 41 Bacteremia
Microbiologically
or clinically
proven local
infections without
bacteremia
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Stryjewski
2005
ALL = 35, AML = 2, Sarcoma =
8, Other solid tumor = 11
PCT, IL6,
IL8
56 Not
stated
Sepsis
Septic shock
Sepsis (positive culture - two
consecutive +ve if CoNS, fever,
tachycardia, or tachypnoea);
septic shock defined as sepsis
plus need for inotropes/
vasopressors
CRP, C-reactive protein; CoNS, coagulase negative staphylococcus; ESR, erythrocyte sedimentation rate; FUO, fever of unknown origin; IL, interleukin; MCP,
monocyte chemoattractant protein; PCT, pro-calcitonin; SAA, serum amyloid protein A; tADA, t- Adenosine Deaminase; TNF, Tumor necrosis factor
  
Potentially relevant articles identified from 
databases 
n = 368 
Excluded articles; n = 296 
  Not cancer = 20 
  Not FNP = 105 
  Not children = 19 
  Not marker = 117 
  No appropriate outcomes = 2 
  Not testing marker = 31 
  Two gate design = 2 
Potentially relevant articles assessed in detail 
n = 72 
Excluded articles; n = 52 
  Not FNP = 9 
  Not children = 7 
  Children not extractable = 18 
  Not marker = 2 
  No appropriate outcomes = 3 
  Data not extractable = 1 
  Not testing marker = 10 
  Duplicate publication = 1 
  Original article not available = 1 
Data extraction undertaken 
n = 27 
Studies with quantitative data available 
n = 25 
Included in quantitative synthesis 
n = 13 
‘Duplicate’ publication, n= 2 
(One erratum for previous article & 
one study published over 2 articles) 
 
Identified from 
reference lists 
n = 7 
Figure 1 Flow diagram of study selection process.
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Detailed analysis of the statistical modeling used in the
original studies revealed potential problems in adjust-
ment of estimates for other factors, limited event-per-
variable ratios, poorly described handling of multiple
episodes and missing data, and use of data-driven
dichotomies in the reporting of test accuracy.
Diagnostic test performance
Data were available for meta-analysis for CRP for micro-
biologically or clinically documented infection; for PCT
assessing microbiologically or clinically documented
infection; and IL6 reporting microbiologically or clini-
cally documented infection, and gram negative bactere-
mia. Individual results for these studies and outcomes
are given in Additional file 3.
Meta-analysis using the three specified approaches
illustrated how the standard, simple approach to pooling
of test accuracy data may be misleading and lead to
clinically inappropriate conclusions.
For studies with similar outcomes and where identical
cut-off values were reported in more than one study,
meta-analysis was undertaken to calculate a single diag-
nostic test accuracy estimate using the standard random
effects bivariate approach: Method 1 (see Table 3 and
Figure 2). This approach is the commonly applied tech-
nique, yet does not take into account the inconsistency
of the full data set (see Methods).
There is marked heterogeneity in the results of this
meta-analysis, with sensitivity heterogeneous in all mar-
kers, and specificity most heterogeneous in PCT and
CRP. This can be appreciated by comparison of the
point estimates and confidence intervals in the y (sensi-
tivity) axis and x (reverse-specificity) axis in Figure 2.
Using the second approach, producing HSROC, it was
possible for CRP and PCT to detect ‘documented infec-
tion’: Method 2. No further HSROC curves were derived
as no other combinations of outcome and biomarker
were available in more than three studies. In this analy-
sis, the threshold variation was not adhered to, as can
be seen in the example of CRP. Figure 3a shows the
curve without threshold, and 3b shows how the values
are not in the order expected. The expectation is that a
higher cut-off produces a lower sensitivity and higher
specificity; this is not the case and so this makes clinical
interpretation of the curve impossible.
The meta-analysis method (Method 3), which maxi-
mizes the use data, including multiple thresholds from
studies using a multinomial random effects model,
demonstrates that these problems arise because of the
inconsistencies in the repor t e dd a t a .A g a i n ,t h eC R P
data are used to demonstrate this (see Figure 4). This
shows that some of the lower thresholds are less sensi-
tive than higher thresholds; for example, using a cut-off
of > 20 mg/dL produced more false negative results
than a cut-off of > 50 mg/dL. These differences are
b e y o n dt h o s ee x p e c t e db yc h a n c ea n dl e dt ot h ea n a -
lyses producing clinically meaningless results. This is
likely to be due to the extreme heterogeneity and sparse
data.
Data on the diagnostic value of nine other markers are
presented in Table 4. IL8 was most frequently described
[27,38,39]. Most of these studies were exploratory, pro-
posing new biomarkers and deriving cut-offs, for exam-
ple, Monocyte chemoattractant protein-1 or Adenosine
deaminase. The predictive value of these biomarkers is
also heterogeneous, and subject to potential biases.
Discussion
This systematic review of the predictive value of serum
markers of inflammation and infection in children pre-
senting with febrile neutropenia found 25 studies report-
ing 14 different markers. Of these, CRP, PCT, IL6 and
IL8 were most commonly examined. The finding of a
diverse range of potentially useful markers, but such lit-
tle consistency across studies, is unfortunately common
in such research [40], and may reflect the relative lack
of coordination in supportive care studies.
The studies presented similar challenges in reporting,
methodology and analysis. Reporting if the test was
interpreted ‘blind’ to the results of the outcome analysis,
and vice-versa, was very poorly reported. Many studies
failed to assess if the marker had supplementary value
above the simple admission data collected by clinicians
at every encounter: age, malignancy, temperature, vital
statistics and blood count. Analysis of the data was
Table 3 Bivariate estimates of diagnostic precision of various biomarkers and outcomes
Marker Outcome Cut-off Sensitivity (95% CI) Specificity (95% CI)
CRP
(7 studies, 731 episodes)
Documented infection > 50 mg/dl 0.65 (0.41 to 0.84) 0.73 (0.63 to 0.82)
PCT
(3 studies, 216 episodes)
Documented infection > 0.2 mg/ml 0.96 (0.05 to 0.99) 0.85 (0.53 to 0.97)
IL6
(3 studies, 457 episodes)
Documented infection > 235 pg/ml 0.68 (0.15 to 0.96) 0.94 (0.84 to 0.98)
IL6
(2 studies, 166 episodes)
Gram negative bacteremia > 1,000 pg/ml 0.78 (0.57 to 0.91) 0.96 (0.92 to 0.99)
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multiple admissions for the same patient. Such an analy-
sis ignores the variation which may be expected from
genetic polymorphisms for the production of the bio-
marker under investigation [39], or in individual genetic
susceptibility to infection [41,42]. The biomarker cut-off
values reported were frequently derived from the dataset
t ow h i c ht h e yw e r et h e na p p l i e d ,w h i c hi sl i k e l yt op r o -
duce significant overestimations of accuracy [43]. The
data were sometimes presented as mean and standard
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Figure 2 Method 1: bivariate pooled estimates of sensitivity and specificity for CRP, PCT and IL6. The plots indicate individual study
estimates of sensitivity and specificity with 95% confidence intervals demonstrated by dashed lines, the solid lines indicate the meta-analysis
result.
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Figure 3 Method 2: hierarchical summary receiver operator curve plots of CRP for the diagnosis of documented infection. a) Circles
weighted according to study precision b) Marker points showing threshold (mg/dl).
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racy were derived. Although this may raise concerns
because of the assumption of a normal distribution,
there is some empiric justification for this procedure
[44].
Quantitative meta-analysis using three approaches
demonstrated how the commonly used, simple techni-
ques may fail to reflect inconsistencies in the whole data
set and so produce misleadingly precise results. The
example of this review is important to recall when
appraising other reviews where inconsistencies may not
have been as extensively investigated.
The analysis undertaken using only the most com-
monly reported cut-off in a restricted number of studies
produced excessively precise results which did not
reflect the uncertainty of the whole data set, and so
should be rejected. A similar problem was found with
the use of data points with different thresholds to pro-
duce a hierarchical summary receiver operator curve
(HSROC). The HSROC modelled by these techniques
does not take into account the actual value of the
thresholds. This is frequently reasonable: it is impossible
to quantify the thresholds used by different radiologists
to call a radiograph ‘positive’ for pneumonia. In cases
where the values are known, an ordered relationship
should be possible to determine, flowing from high to
low cut-offs from left to right on the curve. This
o r d e r e dr e l a t i o n s h i pd i dn o th o l dt r u ef o ra n a l y s e so f
CRP and PCT and so should call into question analyses
in other studies which do not assess whether thresholds
vary according to the implicit structure of the model.
A previously developed [8] technique to undertake the
ordered pooling of all the results was used to attempt to
overcome these difficulties of only selective use of the
data, and of incorrect relationships between test thresh-
olds. This approach failed to produce meaningful results
for the ability of PCT and CRP to identify patients who
developed a documented infection, reflecting the incon-
sistencies and great heterogeneity of the data.
Some of the observed heterogeneity may be due to
differences in measurement between apparently similar
outcomes. While bacteremia is likely to be similarly
reported across the studies, the diagnosis of a soft-tissue
infection may vary between clinicians and centers. Very
few studies reported in detail the exact definitions of the
outcomes they reported. Further variation may have
been introduced by the varying definitions of fever and
neutropenia. In this review, 20 different combinations of
criteria were used to define febrile neutropenia. These
data could not be directly assessed to explore their rela-
tionship with the diagnostic value of the biomarkers, but
as the depth of neutropenia and peak, and duration of
temperature may affect the generation of biomarkers,
the variation may further account for some of the het-
erogeneity. Additionally, although the assay techniques
used in the studies were reported to be similar, there
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Figure 4 Method 3: ROC space plot of CRP for documented infection (all thresholds).
Phillips et al. BMC Medicine 2012, 10:6
http://www.biomedcentral.com/1741-7015/10/6
Page 9 of 13was no calibration of assays across the various studies.
Other differences in the populations studied, such as the
nature of the malignancies, recent surgical interventions
and duration of therapy, may also add heterogeneity to
interpreting markers which are themselves affected by a
malignant disease. A more prosaic reason for heteroge-
neity may be publication bias: the tendency for reports
demonstrating good predictive value to be published
than those showing poor discrimination [45-47].
In order to interpret the information from this
review in a clinically meaningful way, both the esti-
mates of predictive effectiveness and the uncertainty
that surrounds these estimates need to be taken into
account. CRP has been most extensively studied in this
setting; it is a ubiquitous test and the only one which
has been shown to add to the predictive ability of
clinically-based decision rules [26,34]. These studies
chose two differing cut-offs (> 50 mg/dl [26] or > 90
mg/dl [34]). It is at best only moderately discrimina-
tory in the setting of detecting documented infection
(Sensitivity 0.65; 95% CI 0.41 to 0.84, Specificity 0.73;
95% CI 0.63 to 0.82), which is in keeping with
estimates drawn from its value in the detection of ser-
ious bacterial infection in non-neutropenic children
[48], and may be a significant overestimation of its
value. The clinical role of CRP as a screening tool may
be limited, however, if another biomarker is shown to
be a more discriminatory test.
Data from this review and meta-analytic comparisons
of CRP and PCT in the non-neutropenic population
[49] are suggestive of the improved predictive value of
PCT over CRP. This has a strong pathophysiological
basis, as PCT levels are reported to rise within 3 to 4
hours in response to infection as compared with the 24
to 48 hours required for CRP [33]. However, the data
for the improved predictive value of PCT are quite var-
ied (see Additional file 3 and previously published
reviews [13]). This may be related to the degree of neu-
tropenia, as reports from the post-transplant setting
have shown disappointingly poor discrimination [50], or
this again may be due to small studies and publication
bias [47,51]. Based on the data from this review, procal-
citonin cannot yet be recommended for use in routine
clinical practice
Table 4 Estimates of diagnostic precision of various markers and outcomes in single studies.
Citation Marker and
Cutpoint
Outcome Sensitivity
(95% CI)
Specificity
95% CI)
Santolaya 2008 IL8
200
Sepsis 0.49
(0.4 to 0.58)
0.71
(0.67 to 0.75)
Diepold 2008 IL8
30
Prolonged illness 0.87
(0.78 to 0.93)
0.61
(0.42 to 0.76)
Diepold 2008 IL8
90
Bacterial infection 0.64
(0.39 to 0.84)
0.62
(0.52 to 0.71)
El-Maghraby
2007
IL8
62
Documented
infection
0.71
(0.59 to 0.81)
0.77
(0.58 to 0.89)
Lehrnbecher
2004
IL8
320
Documented
infection
0.56
(0.46 to 0.65)
0.79
(0.73 to 0.84)
Lehrnbecher
2004
IL8
500
Documented
infection
0.44
(0.35 to 0.54)
0.89
(0.84 to 0.93)
El-Maghraby
2007
MCP
350
Documented
infection
0.64
(0.52 to 0.75)
0.92
(0.76 to 0.98)
Hitoglou-Hatzi
2005
tADA
35 U/l
Significant bacterial
infection
1.0
(0.88 to 1.0)
1.0
(0.91 to 1.0)
Riikonen 1992 TNF
40
Bacteremia or focal
infection
1.0
(0.88 to 1.0)
0.07
(0.03 to 0.15)
Hodge 2006 IL5
17
Positive blood culture 0.5
(0.22 to 0.79)
Could not
calculate
Hodge 2006 IL5 and 8
combined
> 17 and > 220
Positive blood culture 1.0
(0.68 to 1.0)
0.87
(0.68 to 0.96)
Soker 2001 IL-2R Bacteremia Median (range)
5,230 U/mL (1,120 to 7,600)
1,190 (724 to
5,400)
Soker 2001 TNF-alpha Bacteremia 8.4
(4.0 to 68.2)
7.8
(3.0 to 37.2)
Secmeer 2007 ESR Bacteremia “not statistically significantly different between patients with and without
documented infection”
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tive ability can be advanced for IL6 and IL8 [52]. In this
review, IL6 level shows potential to be a better discrimi-
nator than CRP of those children who will develop a
serious infectious complication. IL8 also appears to have
moderate discriminatory ability and has been used in
combination with clinical data in a small pilot study to
withhold antibiotics to a highly select group of patients
with febrile neutropenia [53]. Both of these cytokines
show promise, and should be subject to further
investigation.
Given the very limited data available for other poten-
tial biomarkers of infection in the setting of pediatric
febrile neutropenia identified by this review, no strong
clinical conclusions for their use can be reached without
further studies.
These conclusions are drawn from an extensive and
detailed systematic review of the available evidence
using advanced techniques of meta-analysis, supplemen-
ted by rational clinical and pathophysiological reasoning.
It should be clearly understood that they are uncertain
and unstable, as only small amounts of new data may
substantially alter these findings.
Conclusions
This review demonstrates flaws in our current under-
standing of the value of biomarkers in the prediction of
adverse outcomes from episodes of febrile neutropenia,
but also provides us with clear opportunities for devel-
opment. All further investigation should estimate the
additional value of biomarker measurements, beyond
the discrimination already achieved by clinical variables.
This should take into account key features of the treat-
ment, for example, stem-cell transplantation and any
clinically defined risk stratification already undertaken.
This includes the use of individual patient data (IPD)
meta-analysis, which shoulda l l o wt h ee f f e c t i v ea d d e d -
value of markers to be measured when the best clinical
data have been taken into account in differing sub-
groups. Such a venture is in progress [54]. The biomar-
kers IL6, IL8 and PCT appear promising, and should
certainly be subject to new primary studies investigating
more thoroughly the prediction of significant infectious
morbidity, which includes both clearly defined infections
and the sepsis syndrome, across a variety of clinical set-
tings. By developing harmonized definitions of outcomes
for such studies, greater confidence could be placed
upon their results. The new SIOP Supportive Care
group is ideally placed to lead on such a venture, and
allow pediatric oncology/hematology to once more push
the boundaries of international, collaborative clinical
research.
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